Spots Global Cancer Trial Database for Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis
Official Title: A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Patients With Actinic Keratosis (AK)
Study ID: NCT01516515
Conditions
Study Description
Brief Summary: This Phase II study is to evaluate the efficacy of SR-T100 gel with 2.3% of SM in Solanum undatum plant extract in patient with Actinic Keratosis (AK).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contour Dermatology & Cosmetic Surgery Center, Rancho Mirage, California, United States
IMMUNOe International Research Centers, Longmont, Colorado, United States
Atlantic Clinical Research Collaborative, West Palm Beach, Florida, United States
Palm Beach Research Center, West Palm Beach, Florida, United States
Suzanne Bruce and Associates,P.A. The Center for Skin Research, Katy, Texas, United States
Pflugerville Dermatology Clinical Research, Pflugerville, Texas, United States
The Education & Research Foundation, Inc, Lynchburg, Virginia, United States
Premier Clinical Research, Spokane, Washington, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
